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Background: Human influenza virus hemagglutinin prefers to use sialic acid (SA) receptors via α-2,6 linkages. The
β-galactoside α-2,6-sialyltransferase I (ST6Gal I) protein is encoded by the ST6GAL1 gene and is responsible for the
addition of α-2,6 linked SA to the Galβ1-4GlcNAc disaccharide of glycans and glycoproteins found on the cellular
surface. Therefore, ST6GAL1 could be a potential target for anti-influenza therapeutics. We used specific small
interfering RNAs (siRNAs) to block expression of ST6GAL1 and limit distribution of SA receptors on the surface of
airway epithelial cells.
Results: The siRNA duplexes we used inhibited ST6GAL1 mRNA expression and subsequent expression of the
encoding protein. As a result, synthesis of α-2,6 SA galactose was inhibited. Adsorption of influenza virus particles to
the surface of cells transfected with appropriate specific siRNAs was significantly reduced. Intracellular viral genome
copy number and virus titer within the supernatant of cells transfected with siRNAs was significantly reduced in a
dose-dependent manner compared with those for untransfected cells and cells transfected with non-specific
siRNAs.
Conclusions: We used siRNAs targeting ST6GAL1 to inhibit the expression of certain cell surface receptors, thereby
preventing virus adsorption. This resulted in the inhibition of human influenza virus infection. Our findings are a
significant development in the identification of potential new anti-influenza drug targets.
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Influenza virus infections are considered a significant
public health problem given that they cause seasonal
epidemics and recurring pandemics [1]. There were
more than 29,000 cases of infections, and 3,000 human
deaths attributed to the 2009 global H1N1 influenza
pandemic [2]. Because of the high mutation rates of the
viral genome, vaccines and drugs initially directed
against the virus often become ineffective [3,4]. Therefore,
measures are urgently needed to prevent and treat influ-
enza virus infections, especially for high-risk groups and
in the event of another pandemic. Certain host cell factors
involved in the viral infection cycle have attracted interest* Correspondence: jeffyah@163.com; nanshan@vip.163.com
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unless otherwise stated.as therapeutic targets because these are crucial for viral in-
fections. Targeting these factors might inhibit infection,
and there is the added advantage that they are less prone
to mutations [5-7].
Sialic acid (SA) molecules, found at the non-reducing
terminal position of glycoproteins or glycolipids on the
surface of cells, are binding targets for influenza A virus
(IAV) hemagglutinin (HAs) [8]. The HAs of human IAVs
preferentially bind to α-2,6 linked SA, which is abundantly
expressed in the human respiratory tract. The HA pro-
teins of avian IAVs prefer α-2,3 linked SA as a receptor, as
it is predominant in the avian enteric tract [9]. The bind-
ing of HA to its appropriate receptor is crucial for the ini-
tiation of infection and therefore serves as a potential
therapeutic target. The novel sialidase fusion protein,
DAS181 (Fludase), enzymatically removes SAs from the
respiratory epithelium and exhibits potent antiviral activity
against influenza A and B viruses [10]. Sialyltransferases. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lated oligosaccharide sequences [11]. Weinstein et al.
concluded that one enzyme, βgalactoside α2,6sialyl-
transferase I (ST6Gal I), encoded by ST6GAL1, was
responsible for the addition of α-2,6 SAs to the Galβ1-
4GlcNAc disaccharide found on the glycans of N-linked
and some O-linked glycoproteins [12]. Lin et al. found
that antisense-oligodeoxynucleotides targeting ST6GAL1
mRNAs could inhibit the enzymatic activity of ST6Gal I,
and reduced 2,6-sialylation at the cell surface [13,14].
Numerous studies involving small interfering RNAs
(siRNAs) in the treatment of viral infections have been
conducted [15-17], including our successful application of
siRNAs to treat severe acute respiratory syndrome
(SARS)-infected rhesus macaques [18]. Qe et al. used siR-
NAs specific for conserved regions of the influenza virus
genome; these proved to be potent inhibitors of influenza
virus replication in vitro and in vivo [19,20]. However, siR-
NAs solely targeting the genes of influenza viruses are un-
likely to be sufficient in eliminating infection because
there is a high possibility of generating resistant mutants.
Therefore siRNAs targeting host cellular determinants
crucial for viral entry and/or replication could be a more
efficacious antiviral therapy.
Our study was designed to evaluate siRNAs targeting
ST6GAL1 in airway epithelial cells. We designed four
siRNA duplexes and screened their ability to down-
regulate ST6GAL1 expression and affect the biosynthesis
of α-2,6-linked SA in human respiratory tract epithelium.
The antiviral effects of selected siRNA duplexes were
demonstrated using viral binding assays, and by determin-
ing cytoplasmic viral genome copy numbers and virus ti-
ters in culture supernatants.
Results
ST6Gal Ι expression in siRNA-transfected A549, HBE, and
HEp-2 respiratory epithelial cells
Using qPCR assays, we determined there was an 80–90%
reduction in ST6GAL1 mRNA expression levels up to
48 h post-transfection (Figure 1A,B). Both ST6GAL1-
siRNA01 and −02 were more potent than the other siRNA
candidates. Their effects were verified using western blot
assays. In cells transfected with the selected ST6GAL1 siR-
NAs, ST6Gal Ι expression was substantially lower than in
those transfected with control siRNAs and untransfected
cells (Figure 1D). This roughly corresponds to the reduc-
tion in mRNA levels as observed by qPCR.
Transduced epithelial cells showed normal levels
of viability
The concentration of ST6GAL1 siRNAs we used (2.5–
25 nM) did not adversely affect the number of viable
cells, nor affect cell morphology (data not shown) of
A549, HBE, and HEp-2 cells (Figure 1E and Additionalfile 1: Figure S1). When we used siRNAs at 50 nM some
cytotoxicity was observed. Based on these results, we used
siRNAs at 10 nM in the remainder of our experiments.
Down-regulation of influenza virus receptors SAα2,6Gal
Expression of SAα2,6Gal receptors was observed on the
surface of cultured human A549 cells (Figure 2A).
Treatment with ST6GAL1 siRNAs significantly reduced
the number of SAα2,6Gal receptors at the cell surface
(Figure 2C) compared with control siRNAs (Figure 2B)
and untransfected cells (Figure 2A). Similar results were
seen for HBE and HEp-2 cells (Additional file 1: Figure S2).
Our FACS analysis of A549 cells revealed that ST6GAL1
siRNA-transduced cells had an 89% decrease in SAα2,6Gal
expression. Cells treated with control siRNAs and untreated
cells displayed normal levels of SAα2,6Gal expression
(Figure 1C).
Receptor specificity of viruses
All virus strains tested bound to CRBCs, which expressed
both α2,3- and α2,6-linked SA. The H9N2 virus preferen-
tially bound to SAα2,3Gal-resialylated CRBCs, whereas
the human H1N1 and seasonal human H3N2 influenza
virus preferentially bound to the SAα2,6Gal-resialylated
CRBCs (Figure 3).
siRNA-transduced respiratory cells were resistant to
viral challenge
A reduction in viral yield was seen in ST6GAL1
siRNA-transduced A549 cells challenged with the H3N2
and pdmH1N1 strains as compared with control cells
(Figure 4A,B). Similar results were observed for HBE
and HEp-2 cells (Additional file 1: Figure S3). No differ-
ences were observed when cells were infected with the
avian H9N2 virus (Figure 4C).
Inhibition of ST6GAL1 expression affects virus binding
and internalization
Virus particles were abundant on the surface of A549 cells
transfected with control siRNAs, and those infected with
viruses (Figure 5A,B). However, there was a reduction in
the number of bound virus particles for cells treated with
ST6GAL1 siRNAs (Figure 5C). The genome copy number
of viruses was reduced following transfection of the vari-
ous cell lines (A549, HBE, and HEp-2) with ST6GAL1 siR-
NAs (Figure 4D) prior to viral infection.The tested siRNAs did not induce an interferon response
The expression of IFN-β in supernatants of siRNA-
transfected cell lines (A549, HBE and HEp-2) was not de-
tected. As a positive control, a long double-stranded RNA
that is known to induce the expression of IFN-β was in-
cluded (Figure 4E).
Figure 1 ST6GAL1-specific siRNAs inhibited ST6Gal 1 expression and SAα2,6Gal synthesis. Respiratory epithelial cells were transfected with
control or ST6GAL1 siRNAs (A) At 48 h post-transfection, ST6GAL1 mRNA expression levels were quantified. (B) Candidate siRNAs reduce ST6GAL1
expression in a dose-dependent manner. (C) FACS analysis showed a decrease in SAα2,6Gal expression on ST6GAL1 siRNA-treated cell surfaces.
(D) Inhibition of ST6Gal Ι expression due to ST6GAL1 siRNAs. (E) We used ST6GAL1 siRNAs at various concentrations and they were not cytotoxic,
except at 50 nM. aP < 0.05.
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In our study, we were able to demonstrate that down-
regulation of the major influenza receptor, SAα2,6Gal, in
respiratory epithelial cells was a promising approach to
prevent viral entry and establishment of an infection.
Most human influenza infections are caused by virus
strains transmitted via an airborne route from the hu-
man respiratory tract, although there are some reports
of avian influenza viruses directly infecting humans
[21,22]. We designed siRNAs targeting ST6GAL1, in an
attempt to inhibit pdmH1N1 and H3N2 virus infection
in HEp-2, HBE, and A549 cells, which are representative
of the upper, middle and lower respiratory tract epithe-
lial cells, respectively, without inducing an interferon
response.
Treatment with siRNAs is not dependent upon a func-
tional immune system. Therefore siRNA therapies could
be as effective in elderly or immunocompromised indi-
viduals as in immunocompetent individuals [23]. The
siRNAs targeting ST6GAL1 that we used in this currentstudy could be ideal in preventing influenza infection in
patient groups with low immunity. Our results pertaining
to virus binding indicate that ST6GAL1-specific siRNAs
reduce the number of IAV virions that attach to epithelial
cells, because of reduced expression of SAα 2,6Gal on the
cell surface.
Recent studies have suggested that some siRNAs could
have side effects [24] that adversely affect cell viability. We
demonstrated that the effective dose (10 nM) of siRNAs,
under the conditions tested, was not toxic to respiratory
epithelial cells in vitro. However, we did notice that ex-
pression levels of receptors were substantially diminished
as a result of siRNA targeting. Influenza viruses naturally
infect epithelial cells in the upper respiratory tract and the
lungs of humans. Thus, siRNAs can be administered by
inhalation. This would result in much higher local siRNA
concentrations than could be achieved by parenteral injec-
tion, without adversely affecting epithelial cells [23]. Stud-
ies focusing on these aspects are currently underway in
our laboratories.
Normal control Non-targeting siRNA(10nM)ST6GAL 1-siRNA(10nM)
Figure 2 Treatment with ST6GAL1 siRNAs inhibited SAα2,6Gal expression on cell surfaces. A549 cells were treated with ST6GAL1 or
control siRNAs. SAα2,6Gal was stained with SNA-FITC (green) and cell nuclei were counterstained with DAPI (blue). (A) Untreated cells. (B) Control
siRNAs. (C) ST6GAL1 siRNAs.
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enza viruses can still infect ST6GAL1 knock-out mice,
achieving similar titers in the lung and trachea as com-
pared with wild-type animals [25]. A possible explanation
for this is that there was greater efficiency of infection as a
result of a deficient systemic influenza-specific humoral
response in these ST6GAL1 knock-out mice [26].
There are two major types of SAα2,3Gal, which differ
in their penultimate bond (Neu5Acα2-3Galβ1-3Gal-
NAc or Neu5Acα2-3Galβ1-4GlcNAc) and these are
synthesized by different enzymes [27-29]. Some human
influenza virus strains propagated in allantoic cavities
are able to bind to both SAα2,6Gal and SAα2,3Gal
[9,25,30]. When recombinant rat α2,3-sialyltransferase
was used to reconstitute sialic acids, only one type ofFigure 3 Receptor specificity of virus strains. (A) Unmodified (left) and VCN
the H3N2 and pdmH1N1 viruses (left). SAα2,3Gal-resialylated CRBCs hemagglu
1:2 dilution.galactose was linked to other glycans through β-1,3 but
not β-1,4 linkages [31-33]; however, it is possible that
other strains maintain the ability to bind to Neu5Acα2-
3Galβ1-4GlcNAc. Thus, SAα2,3Gal (Neu5Acα2-3Galβ1-
4GlcNAc) present in these mice can compensate for the
loss of SAα2,6Gal [34]. Monteerarat et al. [35] reported
that suppression of SAα2,3Gal expression by siRNAs
against another sialyltransferase, β-galactoside α-2,3-
sialyltransferase 4 (ST3GAL4) could inhibit H5N1 avian
influenza virus infection. The findings from our current
study support the conclusions of Monteerarat et al., and
we have further extended these to airway epithelial tar-
gets of human IAV infection. A combination of these
two types of siRNAs might result in broader spectrum
synergistic activities, depending upon their targets.A-treated CRBCs (right). (B) SAα2,6Gal-resialylated CRBCs hemagglutinate





















































































































































































Figure 4 ST6GAL1 siRNA-transduced respiratory cells resisted human influenza virus challenge and did not induce an interferon
response. Transduced A549 cells were challenged with H3N2, pdmH1N1, or H9N2 viruses. (A) A reduction in viral yield was seen in ST6GAL1
siRNA-transduced cells infected with and pdmH1N1 (B) H3N2 influenza viruses. aP < 0.05. (C) Viral yield was not affected when cells were
infected with the avian H9N2 virus. (D) Treatment with ST6GAL1 siRNAs resulted in a reduced capacity for viral replication during virus entry.
aP < 0.05. (E) ELISAs were used to measure levels of IFN-β production following treatment with siRNAs.
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We demonstrated the in vitro efficacy of siRNAs targeting
ST6GAL1 in respiratory epithelial cells for the prevention
of IAV infections at the virus entry stage. Further in vivo
preclinical testing is required to determine the suitability
of these siRNAs for use in humans.Normal control Non-targeting s
Figure 5 Virus particle binding assays. Virus particles binding to the surfac
siRNAs (B, black arrow). The binding of virus particles to the cell surface was aMethods
Cells and viruses
We used Madin–Darby canine kidney (MDCK) cells for
virus propagation and 50% tissue culture-infective dose
(TCID50) titration assays. MDCK cells were in minimal es-
sential medium (MEM; Gibco, Carlsbad, CA, USA)iRNA(10nM) ST6GAL 1-siRNA(10nM)
e of untransfected cells (A, black arrow), and cells treated with control
dversely affected by treating with ST6GAL1 siRNAs (C, black arrow).
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Gibco), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (Gibco) at 37°C/5% CO2. The A549 human lung
carcinoma, human bronchial epithelium (HBE), and hu-
man laryngeal epidermoid carcinome (HEp-2) cells were
used for transfection experiments. These cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10% FBS, 100 U/mL
penicillin, and 100 μg/mL streptomycin at 37°C 5% CO2.
We used a 2009 pandemic influenza A (H1N1) virus
(pdmH1N1), strain A/Guangzhou/GIRD07/2009 (Gen-
Bank Accession No. HM_014326-HM_014333). A sea-
sonal H3N2 influenza A virus (A/Guangdong/520/2009)
was isolated from a patient with influenza-like symptoms.
An influenza A H9N2 isolate (A/Chicken/Guangdong/SS/
94) was kindly provided by South China Agricultural Uni-
versity. The pdmH1N1 and H3N2 viruses were grown in
MDCK cells at 35°C, while the H9N2 virus was propa-
gated in allantoic cavities of 10-day-old embryonated hens’
eggs at 37°C. All experiments with pdmH1N1 and H9N2
viruses were conducted under biosecurity level three con-
ditions, and higher.
Preparation and transfection of siRNAs
The siRNAs against ST6GAL1 were designed using
BLOCK-iT™ RNAi Designer [36] and synthesized by
Invitrogen ( Invitrogen, Carlsbad, CA, USA). Sequences
are available in Additional file 1: Table S1. As a negative
control, we used non-targeting Allstars® siRNAs (Qiagen,
Valencia, CA, USA). All siRNA duplexes were double-
stranded RNA molecules comprising 21 nt with a dTdT
overhang at the 3’ ends [37]. Target sequences were sub-
jected to a Basic Local Alignment Search Tool (BLAST)
search against GenBank to ensure they were unique to
ST6GAL1. Airway epithelial cell lines (A549, HBE, and
HEp-2) were transfected with either ST6GAL1 or non-
targeting Allstars® siRNAs using Lipofectamine® RNAiMax
(Invitrogen) according to the manufacturer’s instructions.
At different time points post-transfection, cells were either
infected with influenza virus or harvested for downstream
experiments.
Detection of ST6GAL1 and ST6Gal I
Expression of ST6GAL1 was detected using real-time re-
verse transcription polymerase chain reaction (qPCR) as-
says. Expression of the ST6Gal I protein was determined by
western blotting. Respiratory epithelial cells (A549, HBE,
and HEp-2) were transfected with control or ST6GAL1 siR-
NAs (2.5–50 nmol). At 48 h post-transfection we used an
RNeasy Mini kit (Qiagen) for RNA extraction according to
the manufacturer’s instructions. The extracted total RNA
(500 ng/sample) was then used for cDNA synthesis. The
resulting cDNA was amplified in a 20-μL reaction contain-
ing ST6GAL1-specific forward (0.25 μmol) and reverse(0.25 μmol) primers (Additional file 1: Table S2), and 1×
Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA). Reactions were subjected to thermal
cycling with an IQ5 System (Bio-Rad, Hercules, CA,
USA) involving an initial 10-min denaturation step at
95°C, followed by 40 cycles of 95°C for 15 s and 60°C
for 60 s. Fluorescence signals from these reactions
were captured at the end of the 60°C extension step for
each cycle. To determine the specificity of the assay,
amplicons were subject to melting curve analysis after
the 40th cycle (65–95°C, 0.1°C/s). Our data were ana-
lyzed using the 2-ΔΔCT method, according to the man-
ufacturer’s instructions, with ST6GAL1 expression
levels normalized to β-actin mRNA levels.
After transfection for 48 h, A549 cells were lysed in 50
mM Tris–HCl buffer (pH 7.4) containing 1% Triton X-
100, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 20
μg/mL leupeptin, 4 mM sodium fluoride, and 200 μM so-
dium pervanadate. Protein concentrations in the lysates
were determined with a BCA assay kit (Pierce, Rockford,
IL, USA). Proteins in lysates were resolved under reducing
conditions for sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). We probed polyvinylidene
fluoride (PVDF) membranes with 5 μg/mL of a rabbit
antihuman ST6Gal Ι polyclonal antibody (Abcam,
Cambridge, MA, USA) followed by a horseradish per-
oxidase (HRP)conjugated antirabbit IgG secondary anti-
body(Abcam). Specific signals were visualized using an ECL
kit (Pierce). Protein concentrations between wells were nor-
malized using HRP-conjugated β-actin-specific monoclonal
antibodies (Sigma-Aldrich, St. Louis, MO, USA).
Cell viability
Cultured cells in the logarithmic growth phase were
trypsinized, seeded into 96-well plates, and transfected
with ST6GAL1 (2.5–50 nmol) or control (10 nmol) siR-
NAs. At 24, 48, and 72 h post-transfection, cell viability
was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assays (Sigma-
Aldrich). The absorbance at 492 nm was measured in a
spectrophotometer (Molecular Devices, Palo Alto, CA,
USA). Background values were subtracted from the aver-
age absorbance value obtained for each siRNA treatment
and then compared with the value obtained when siR-
NAs were absent (100% viability). Each assay was per-
formed in duplicate in at least four wells.
Detection of α-2,6 linked SA on the cell surface
The A549, HBE, and HEp-2 cells were treated with
ST6GAL1 or control siRNAs and cultured for 72 h. Cells
were washed with phosphate-buffered saline (PBS) and
fixed in 3.7% formaldehyde in PBS for 30 min. For de-
tection of sialic acid residues on the surface of cells, ap-
ical monolayers were blocked with 3% bovine serum
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30 min and then incubated with 5 μg/mL fluorescein iso-
thiocyanate (FITC)-conjugated Sambucus nigra lectin
(SNA; Vector Laboratories, Burlingame, CA, USA) for
1 h. To confirm the specificity of lectin binding, mono-
layers were treated with 50 mU Vibrio cholerae neuramin-
idase (VCNA; Roche, Almere, Netherlands) for 1 h prior
to fixation and then examined with a rapid-scanning con-
focal laser microscope (Nikon Corp, Tokyo, Japan).
Flow cytometry
Approximately 106 cells transfected with control or
ST6GAL1 siRNAs were scraped from the culture surface
and washed twice with PBS containing 10 mM glycine,
and then washed once with buffer 1 (50 mM Tris–HCl,
0.15 M NaCl, 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2,
pH 7.5). Cells were blocked with 3% BSA-PBS for 1 h on
ice and washed in the same manner as described above.
After centrifugation, the cell pellet was incubated with
FITC-conjugated SNA at room temperature for 30 min,
then washed and fixed with 1% paraformaldehyde. After
another three washes with PBS, mean fluorescence in-
tensities were determined on a fluorescence-activated
cell sorter (FACS) Calibur flow cytometer (BD, San Jose,
CA, USA) by counting a minimum of 10,000 events.
Receptor specificity of virus strains
To study the receptor-binding properties of the virus
strains used, we enzymatically modified chicken red blood
cells (CRBCs) to express either sialic acid (SA)-α2,6-Gal-
actose (Gal) or SAα2,3Gal as previously described [38,39]
with minor modifications. Briefly, SA was removed from
100 μL of 10% CRBCs using 50 mU VCNA at 37°C for
1 h. Subsequent resialylation was performed using 50 μL
of 0.5 mU α2,3-(N)-sialyltransferase (Calbiochem, La Jolla,
CA, USA) or 125 μL of 2 mU α2,6-( N)-sialyltransferase
(Japan Tobacco, Shizuoka, Japan), and 1.5 mM cytidine
monophospho-N-acetylneuraminic (CMP) sialic acid
(Sigma-Aldrich) at 37°C for 30 or 60 min, respectively.
Receptor specificity of the virus strains was then deter-
mined using standard hemagglutination assays with
the modified CRBCs.
Influenza virus challenge of ST6GAL1-siRNA transduced
epithelial cells
All challenge experiments were carried out at a multiplicity
of infection (MOI) of 0.01 for 1 h in the presence of N-p-
Tosyl-L-phenylalanine chloromethyl ketone (TPCK)-tryp-
sin (Sigma-Aldrich). Viral supernatants were harvested at
various time points post-infection for TCID50 assays. To
obtain dose–response curves, a dilution series of siRNAs
were added to cells in 96-well plates in triplicate. Cells
were challenged and supernatants were examined as de-
scribed above [40].The titer of viruses in supernatants were determined
using TCID50 assays as previously described [20]. Briefly,
MDCK cells were seeded onto flat-bottom 96-well plates
(3 × 104 cells/well); 24 h later, serum-containing medium
was removed and 25 μL of virus-containing supernatants
(serially diluted ten-fold from 10° to10 −8) was added to
wells in triplicate. After incubation for 1 h, 175 μL of in-
fection medium containing TPCK-trypsin (1.25 μg/mL)
was added to each well. After incubation for 48 h at 37°C,
the presence or absence of virus in culture supernatants
was determined by hemagglutination of CRBCs. Virus ti-
ters were determined by interpolation of the dilution end-
point that infected 50% of wells. Virus titers are presented
as log10 TCID50.
Electron microscopy
Cells were transfected with control or ST6GAL1 siRNAs,
then infected with virus at an MOI of 50, and chilled at 4°C
for 90 min. Infected cells were harvested and washed three
times with PBS, then fixed with 3% glutaraldehyde for
45 min at room temperature, and post-fixed with 1% os-
mium tetroxide. Fixed cells were dehydrated with increas-
ing concentrations of acetone from 30% to 100% and
embedded in an epoxy resin. Polymerization was conducted
at 60°C for 48 h. Ultrathin sections were stained with uranyl
acetate and lead citrate, and sections viewed and photo-
graphed with a Hitachi H-800 transmission electron micro-
scope (Hitachi Co., Tokyo, Japan).Quantitation of viral genome copies by qPCR
We extracted RNA 2 h after virus infection using a
QIAamp RNA isolation kit (Qiagen). First-strand cDNA
was synthesized using RNAse H+ reverse transcriptase
(Invitrogen) and random primers. We then used 2 μL of
cDNA for each qPCR assay, along with primers (Additional
file 1: Table S2), fluorescent probe, and Master Mix (Ap-
plied Biosystems). Samples were subjected to thermal cyc-
ling on an IQ5 System (Bio-Rad, Hercules, CA, USA): 42°C
for 5 min; 95°C for 10 s; and 40 cycles of 95°C for 5 s and
60°C for 30 s. Expression levels of viral RNAs were normal-
ized to the constitutive expression of ribonucleoprotein. All
measurements were conducted three times for statistical
analysis.IFN-β assays
The A549, HBE, and HEp-2 cells were transfected with ei-
ther control or ST6GAL1 siRNAs (10 nM). We measured
the levels of IFN-β in culture supernatants 24 h later using
an enzyme-linked immunosorbent assay (ELISA; PBL Bio-
medical Laboratories, Piscataway, NJ, USA). A long double-
stranded RNA that induced the expression of IFN-β used
as a positive control.
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All statistical analyses were performed using SPSS 12.0
(SPSS Inc., Chicago, IL, USA). The significance of variabil-
ity among experimental groups was determined using
one-way ANOVA, the paired t-test, or the Mann–Whitney
U test. All differences were considered statistically signifi-
cant if the P-value was less than 0.05.Additional file
Additional file 1: Table S1. Nomenclature of 4 candidate siRNA
duplexes targeting ST6GAL1 gene. Table S2. Real time RT-PCR primers
and probes. Figure S1. Cells viability. Figure S2. Down regulation of
influenza virus receptors SA α 2,6Gal on transduced respiratory epithelium
(HBE, Hep-2). Figure S3. Targeted siRNA transduced respiratory epitheliums
resist influenza virus challenge.Competing interests
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